ImaginAb, an Inglewood, CA-based immuno-oncology imaging company, raised an additional $8m in equity funding.
The round was led by Adage Capital, with participation from the Parker Institute for Cancer Immunotherapy, NVF, Cycad Group, Nextech Invest, and Jim Pallotta of the Raptor Group.
The new funds will be used to accelerate human clinical trials and to implement centralized manufacturing.
Led by Martyn Coombs, CEO, ImaginAb provides actionable insight into patient selection and treatment progress for cancer immunotherapy, by engineering antibody fragments – called minibodies – that maintain the specificity of full-length antibodies while remaining inert in the body. Used with PET scan technology, these novel minibodies illuminate high-value molecular targets, providing physicians with a whole-body picture of immune activity.
The company is also advancing a CD8 T Cell imaging agent designed to non-invasively determine changes in CD8+ T cell tumor infiltrates induced by immuno-oncological treatments. This approach has the potential to guide the development of immuno-modulatory agents as well as assess early on whether a patient responds to such a treatment.